American Century Companies’s Palvella Therapeutics PVLA Stock Holding History

American Century Companies’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,246	Closed	-$3.1M	–	1335
2019 Q2	$3.1M	Sell	8,246 -1,280	-13%	-$382K	﹤0.01%	939
2019 Q1	$2.55M	Buy	9,526 +1,392	+17%	+$331K	﹤0.01%	955
2018 Q4	$1.73M	Buy	8,134 +2,220	+38%	+$689K	﹤0.01%	994
2018 Q3	$2.65M	Buy	5,914 +67	+1%	+$29.1K	﹤0.01%	981
2018 Q2	$2.37M	Buy	5,847 +5,391	+1,182%	+$2.57M	﹤0.01%	994
2018 Q1	$249K	Buy	+456	New	+$282K	﹤0.01%	1212

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

American Century Companies's PVLA Position: Q3 2019 in Review

American Century Companies sold out of Palvella Therapeutics (PVLA) in Q3 2019, closing a stake of 8,246 shares — an estimated $3.1M sold.

American Century Companies first reported a position in PVLA in Q1 2018 and held it in 6 quarters. The position peaked at $3.1M in Q2 2019. 98 funds tracked by Wall St. Rank hold PVLA as of Q3 2019.

American Century Companies reported no remaining Palvella Therapeutics position as of Q3 2019 after selling out during the quarter.
American Century Companies sold 8,246 Palvella Therapeutics shares in Q3 2019, an estimated $3.1M.
American Century Companies first reported a position in Palvella Therapeutics in Q1 2018 and held it in 6 quarters.
American Century Companies's Palvella Therapeutics position peaked at $3.1M in Q2 2019.
98 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2019.

Based on American Century Companies's 13F filing for Q3 2019, filed 13 Nov 2019.